James Tyler - Aug 5, 2022 Form 4 Insider Report for SANUWAVE Health, Inc. (SNWV)

Role
Director
Signature
/s/ Griffin D. Foster as Attorney-in-Fact for James Tyler
Stock symbol
SNWV
Transactions as of
Aug 5, 2022
Transactions value $
$45,000
Form type
4
Date filed
3/4/2025, 04:13 PM
Previous filing
Mar 4, 2025
Next filing
Apr 7, 2025
SEC
View on sec.gov

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNWV Future Advance Convertible Promissory Note Award $45K $45K Aug 5, 2022 Common Stock 3K $15.00 Direct F3
transaction SNWV Future Advance Convertible Promissory Note Conversion of derivative security -$51.8K 0 Aug 5, 2023 Common Stock 3.45K $15.00 Direct F1
transaction SNWV Common Stock Purchase Warrant (right to buy) Award +3K 3K Aug 5, 2022 Common Stock 3K $15.00 Direct F3
transaction SNWV Common Stock Purchase Warrant (right to buy) Disposed to Issuer -3K -100% 0 Oct 18, 2024 Common Stock 3K $15.00 Direct F2
transaction SNWV Common Stock Purchase Warrant (right to buy) Award +3K 3K Aug 5, 2022 Common Stock 3K $25.13 Direct F3
transaction SNWV Common Stock Purchase Warrant (right to buy) Disposed to Issuer -3K -100% 0 Oct 18, 2024 Common Stock 3K $25.13 Direct F2
transaction SNWV Stock Option (right to buy) Award $0 +41.3K $0.00 41.3K Oct 22, 2024 Common Stock 41.3K $14.20 Direct F4
transaction SNWV Stock Option (right to buy) Award $0 +1.56K $0.00 1.56K Dec 31, 2024 Common Stock 1.56K $22.76 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the terms of the Future Advance Convertible Promissory Note issued by SANUWAVE Health, Inc. (the "Company") on August 5, 2022, all principal and accrued interest due as of the maturity date, August 5, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share.
F2 On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's warrants were exchanged for an aggregate of 5,250 shares of common stock pursuant to a letter agreement between the reporting person and the Company.
F3 On August 5, 2022, in exchange for $45,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $45,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 3,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 3,000 shares of common stock at an exercise price of approximately $25.13 per share).
F4 Options will vest over a period of three years in 12 equal installments on each quarterly anniversary of the grant date.
F5 Options were fully vested at the grant date.

Remarks:

All share amounts, exercise prices and conversion prices herein have been retroactively adjusted to reflect the 1-for-375 reverse stock split of the Company's common stock which occurred on October 18, 2024.